GlassScriptPhysician profile
Joel S Smith
NPI 1134239270
$10,301.24
in general payments reported to CMS, 2019-2025
59 companies · $2,264 in 2025
The $2,264 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,773 · 2022: $2,578 · 2023: $2,041 · 2024: $1,645 · 2025: $2,264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,950.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,950.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,337.62 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $919.70 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $823.24 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $676.07 | 2021-2024 | Spravato |
| Novartis Pharmaceuticals Corporation | $523.85 | 2021-2025 | |
| Abbvie INC. | $478.14 | 2021-2025 | |
| Lilly USA, LLC | $438.05 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $362.74 | 2022-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $318.30 | 2021-2025 | Xifaxan, Trulance, Cycloset |
| Astrazeneca Pharmaceuticals LP | $276.18 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $256.77 | 2021-2025 | Jardiance |
| Amgen INC. | $235.49 | 2021-2025 | Repatha, Otezla, Evenity |
| Astellas Pharma US INC | $204.71 | 2021-2024 | Veozah, Myrbetriq |
| Biohaven Pharmaceutical Holding Company LTD. | $192.47 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $143.93 | 2021 |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $140.77 | 2022-2025 | Gvoke Hypopen, Keveyis |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $132.01 | 2022-2025 | Caplyta |
| Amarin Pharma, INC. | $117.70 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $112.93 | 2021-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $106.53 | 2022-2025 | Camzyos, Eliquis |
| Esperion Therapeutics, INC. | $104.57 | 2021-2022 | |
| Boston Scientific Corporation | $96.85 | 2025 | Wavewriter Alpha Prime 16 |
| Supernus Pharmaceuticals, INC. | $94.65 | 2022-2025 | Qelbree, Xyosted, Tlando |
| Corcept Therapeutics | $84.81 | 2023-2025 | Korlym |
| Merck Sharp & Dohme LLC | $69.98 | 2021-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Phathom Pharmaceuticals, INC. | $68.55 | 2023-2025 | Voquezna |
| Inspire Medical Systems, INC. | $65.09 | 2023-2025 | Inspire |
| Jazz Pharmaceuticals INC. | $60.17 | 2022 | |
| Lundbeck LLC | $59.45 | 2021-2024 | Rexulti |
| Biogen, INC. | $53.21 | 2025 | Skyclarys |
| Antares Pharma, INC. | $47.38 | 2022 | |
| Medtronic, INC. | $45.27 | 2024 | Kyphon Express II Kyphopak Tray |
| Optinose US, INC. | $44.95 | 2024 | |
| Sumitomo Pharma America, INC. | $40.89 | 2025 | Gemtesa |
| Glaxosmithkline, LLC. | $37.17 | 2021-2025 | Arexvy, Shingrix |
| Mylan Specialty L.P. | $36.86 | 2021-2023 | Yupelri |
| Dexcom, INC. | $34.48 | 2025 | Dexcom G6 Transmitter |
| Horizon Therapeutics Plc | $31.02 | 2023 | Krystexxa |
| Idorsia Pharmaceuticals US INC | $30.73 | 2022-2023 | Quviviq |
| Exact Sciences Corporation | $28.90 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Paratek Pharmaceuticals, INC. | $28.44 | 2023 | Nuzyra |
| Sanofi-Aventis U.S. LLC | $27.42 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $25.11 | 2021 | |
| Eisai INC. | $24.62 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $24.10 | 2024 | Rexulti |
| Corium, LLC | $22.68 | 2023 | Azstarys |
| Seqirus USA INC | $22.21 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Neurocrine Biosciences, INC. | $20.73 | 2022 | |
| Nevro Corp. | $20.59 | 2023 | Senza |
| Insulet Corporation | $19.82 | 2024 | Omnipod |
| Evoke Pharma, INC. | $18.95 | 2022 | |
| Upsher-Smith Laboratories LLC | $18.94 | 2021 | |
| Shield Therapeutics INC | $16.99 | 2023 | Accrufer |
| Halozyme INC | $15.45 | 2023 | |
| Viatris Specialty LLC | $15.15 | 2025 | Yupelri |
| Ibsa Pharma INC. | $15.10 | 2023 | Tirosint, Licart |
| Saluda Medical Americas, INC. | $14.69 | 2025 | Evoke |
| Arbor Pharmaceuticals, INC. | $13.46 | 2021 | |
| Genentech USA, INC. | $4.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.